Company / Capital Expenditures
NEKTAR THERAPEUTICS Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$171.0K
FY2025
5-year range
$171.0K / $15.0M
FY2021-FY2025
Trend
-80.2%
vs FY2024
Sector context
#161 of 194
Health Care
What the data says
NEKTAR THERAPEUTICS's capital expenditures of $171,000 is lower than 83% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $171,000 in FY2025 to $15M in FY2023.
Based on SEC 10-K filings.
$171,000 in FY2025 with a 5-year CAGR of -58.7%.
Declined from $15M to $171,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -68.9%
- 5-Year CAGR
- -58.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 194This company $171.0K Sector average $117.5M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -58.7%, indicating a declining trend.
- In FY2025, capital expenditures decreased 80.2% year-over-year.
- Ranks #161 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $171.0K | -80.2% |
| FY2024 | $865.0K | -94.2% |
| FY2023 | $15.0M | +164.1% |
| FY2022 | $5.7M | -62.1% |
| FY2021 | $15.0M | +5.3% |
| FY2020 | $14.2M | +47.2% |
| FY2019 | $9.7M | +51.4% |
| FY2018 | $6.4M | -33.9% |
| FY2017 | $9.7M | -3.0% |
| FY2016 | $10.0M | -10.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026